All Articles Written by Eric Silber
WHAT'S HAPPENING IN RICHMOND AFFECTS US ALL!
HR2616
AKA "THE PROTECT KIDS ACT" Legislation addressing parental notification requirements and gender identity policies in public schools has passed the U.S. House of Representatives with support from CD7 Congressman Eugene Vindman. |
H.R. 2616, known as the "Stopping Indoctrination and Protecting Kids Act" or PROTECT Kids Act, was approved by the House in May 2026. The bill would condition certain federal education funding on schools obtaining parental consent before changing a student's gender markers, preferred name, or pronouns in official school records. The legislation also contains provisions restricting the use of federal education funds for instruction related to what the bill defines as "gender ideology."
Representative Vindman was one of eight House Democrats who joined Republicans in voting for the measure. Most House Democrats voted against the legislation.
In a statement following the vote, Vindman said his support was rooted in a belief that parents should be involved in decisions affecting their children at school. He stated that, as a parent of two public school students, he believes parents should be "at the center" of decisions involving school records, academics, and athletics. Vindman also acknowledged provisions in the legislation with which he disagreed and indicated he would seek changes to those portions moving forward, but said they weren't problematic enough to remove his support.
Supporters of the legislation argue that it increases transparency between schools and families and reinforces parental involvement in educational decisions. Republican backers of the bill described it as a measure designed to strengthen parental rights and ensure families are informed about significant decisions affecting their children.
Opposition to the legislation has been substantial among Democratic lawmakers, civil rights organizations, LGBTQ+ advocacy groups, and education advocates. Critics argue that the bill could force schools to disclose information about transgender students to parents even in situations where a student may not feel safe doing so. Opponents have also raised concerns that restrictions on discussions of gender identity could affect educational content, student support services, and school policies related to LGBTQ+ students.
The vote generated significant discussion among Democrats in Virginia and nationally. Some supporters of Representative Vindman's vote praised his emphasis on parental involvement, while critics questioned how the vote aligns with broader Democratic positions on LGBTQ+ rights and student privacy. Advocacy organizations and constituents have continued to debate the legislation's potential impact on students, families, educators, and school districts.
The bill has not yet become law, and likely never will. Under current Senate rules, it requires 60% support in the upper chamber for passage, which would require at least 7 Democratic Senators to support the legislation, a threshold deemed highly unlikely by political scientists and by both supporters and opponents of the bill.
Representative Vindman was one of eight House Democrats who joined Republicans in voting for the measure. Most House Democrats voted against the legislation.
In a statement following the vote, Vindman said his support was rooted in a belief that parents should be involved in decisions affecting their children at school. He stated that, as a parent of two public school students, he believes parents should be "at the center" of decisions involving school records, academics, and athletics. Vindman also acknowledged provisions in the legislation with which he disagreed and indicated he would seek changes to those portions moving forward, but said they weren't problematic enough to remove his support.
Supporters of the legislation argue that it increases transparency between schools and families and reinforces parental involvement in educational decisions. Republican backers of the bill described it as a measure designed to strengthen parental rights and ensure families are informed about significant decisions affecting their children.
Opposition to the legislation has been substantial among Democratic lawmakers, civil rights organizations, LGBTQ+ advocacy groups, and education advocates. Critics argue that the bill could force schools to disclose information about transgender students to parents even in situations where a student may not feel safe doing so. Opponents have also raised concerns that restrictions on discussions of gender identity could affect educational content, student support services, and school policies related to LGBTQ+ students.
The vote generated significant discussion among Democrats in Virginia and nationally. Some supporters of Representative Vindman's vote praised his emphasis on parental involvement, while critics questioned how the vote aligns with broader Democratic positions on LGBTQ+ rights and student privacy. Advocacy organizations and constituents have continued to debate the legislation's potential impact on students, families, educators, and school districts.
The bill has not yet become law, and likely never will. Under current Senate rules, it requires 60% support in the upper chamber for passage, which would require at least 7 Democratic Senators to support the legislation, a threshold deemed highly unlikely by political scientists and by both supporters and opponents of the bill.
|
|
|
Senate Bill 271 and House Bill 483
A major healthcare affordability proposal about Prescription Drug prices passed by the Virginia General Assembly this session will not become law after Governor Abigail Spanberger announced plans to veto the legislation.
The bill, introduced as Senate Bill 271 and House Bill 483, would have created a Prescription Drug Affordability Board (PDAB) within Virginia's State Department of Health. The proposed board would have reviewed certain high-cost prescription medications, and, under specific conditions, would have been authorized to establish upper payment limits tied to federally negotiated drug prices.
The legislation was sponsored in the Senate by Senator Creigh Deeds (D) and in the House by Delegate Carrie Delaney (D). It received bipartisan support in both chambers of the General Assembly.
Supporters of the bill argue that it represented a direct effort to address rising prescription drug costs for Virginians. Organizations including the AARP publicly supported the proposal, citing concerns about affordability for seniors and families facing increasing medication expenses.
Opposition to the legislation came from several pharmaceutical industry groups and healthcare policy organizations (Big Pharma). Critics argue that the board's authority to establish upper payment limits could create unintended consequences involving prescription drug access, insurance markets, or pharmaceutical innovation. Lobbying groups tied to these critics have spent significant amounts of money against this bill.
Before issuing the veto, Governor Spanberger proposed amendments that would have substantially changed the structure of the board. Her amendments would have limited the board's authority and delayed implementation of binding pricing actions pending additional legislative approval. The General Assembly declined to adopt these amendments.
Because of the disagreements between the governor and the General Assembly, Spanberger vetoed the bill. In statements surrounding the veto decision the Governor's office indicated that while the administration supports efforts to reduce healthcare costs, concerns remained about whether the legislation would guarantee direct savings for patients and whether additional policy refinement was needed before implementation.
The veto has prompted discussion among Democrats and healthcare advocates across Virginia. Some lawmakers and advocacy groups expressed disappointment, noting that prescription drug affordability was a major issue during recent statewide campaigns. Others have argued that the governor's concerns regarding implementation oversight deserve further consideration. At this stage, the legislation will not take effect unless lawmakers pursue further action in a future legislative session.
A major healthcare affordability proposal about Prescription Drug prices passed by the Virginia General Assembly this session will not become law after Governor Abigail Spanberger announced plans to veto the legislation.
The bill, introduced as Senate Bill 271 and House Bill 483, would have created a Prescription Drug Affordability Board (PDAB) within Virginia's State Department of Health. The proposed board would have reviewed certain high-cost prescription medications, and, under specific conditions, would have been authorized to establish upper payment limits tied to federally negotiated drug prices.
The legislation was sponsored in the Senate by Senator Creigh Deeds (D) and in the House by Delegate Carrie Delaney (D). It received bipartisan support in both chambers of the General Assembly.
Supporters of the bill argue that it represented a direct effort to address rising prescription drug costs for Virginians. Organizations including the AARP publicly supported the proposal, citing concerns about affordability for seniors and families facing increasing medication expenses.
Opposition to the legislation came from several pharmaceutical industry groups and healthcare policy organizations (Big Pharma). Critics argue that the board's authority to establish upper payment limits could create unintended consequences involving prescription drug access, insurance markets, or pharmaceutical innovation. Lobbying groups tied to these critics have spent significant amounts of money against this bill.
Before issuing the veto, Governor Spanberger proposed amendments that would have substantially changed the structure of the board. Her amendments would have limited the board's authority and delayed implementation of binding pricing actions pending additional legislative approval. The General Assembly declined to adopt these amendments.
Because of the disagreements between the governor and the General Assembly, Spanberger vetoed the bill. In statements surrounding the veto decision the Governor's office indicated that while the administration supports efforts to reduce healthcare costs, concerns remained about whether the legislation would guarantee direct savings for patients and whether additional policy refinement was needed before implementation.
The veto has prompted discussion among Democrats and healthcare advocates across Virginia. Some lawmakers and advocacy groups expressed disappointment, noting that prescription drug affordability was a major issue during recent statewide campaigns. Others have argued that the governor's concerns regarding implementation oversight deserve further consideration. At this stage, the legislation will not take effect unless lawmakers pursue further action in a future legislative session.
Senate Bill 542 and House Bill 642
Legislation that would have established a regulated retail cannabis market here in the Commonwealth of Virginia has been vetoed by Governor Abigail Spanberger.
The bill (H.B. 642 and S.B. 542) passed during the current session of the Virginia General Assembly, sought to create a legal framework for the licensed cultivation, distribution, and retail sale of recreational cannabis in Virginia. While personal possession and limited home cultivation of marijuana remain legal under existing Virginia law, the Commonwealth currently does not have a legal retail marketplace for recreational cannabis purchases.
Supporters of the legislation argued that establishing a regulated market would reduce illicit market activity, generate substantial tax revenue for the state, and establish clearer rules for businesses and law enforcement. Advocates also pointed to neighboring states (like Maryland) that have already implemented regulated cannabis markets.
The proposal included provisions involving licensing requirements, taxation structures, product testing standards, advertising regulations, and oversight by state regulatory agencies. Some versions of the legislation also included social equity provisions aimed at expanding participation opportunities for communities disproportionately affected by prior marijuana enforcement policies.
Opposition to the bill came from a range of groups and lawmakers who raised concerns about public health, impaired driving, youth access, workplace safety, and the long-term effects of expanding commercial cannabis availability. Some critics also argued that Virginia should move more slowly before creating a full retail system.
Before issuing the veto, Governor Spanberger proposed amendments that would have delayed implementation timelines and added additional regulatory review requirements. The General Assembly rejected those proposals.
In statements surrounding the veto, the governor’s office indicated that concerns remained regarding the pace of implementation, regulatory preparedness, public safety considerations, and whether the Commonwealth had sufficient infrastructure in place to oversee a statewide retail cannabis market.
The veto has generated discussion and discontent among Virginia Democrats, advocacy groups, local officials, and voters across the Commonwealth. Some supporters of legalization expressed disappointment and anger, noting that Virginia had already legalized possession without creating a legal method for adults to purchase cannabis products. Others supported the governor’s cautious approach and argued that additional planning and safeguards may still be necessary before retail sales are authorized.
Unless future legislation is passed and signed into law, Virginia will continue operating under its current system in which adult possession of limited amounts of marijuana is legal, but retail recreational sales remain prohibited.
OUR MOST RECENT PUBLICATION |
|
